Clinical Trial Update: Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated Tarceva (erlotinib) as surgical adjuvant therapy for resectable stage IIIA(N2) and IIIB NSCLC; the study was terminated and results we…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2011-06-03